Research shows a promising new method to reduce graft-versus-host-disease after bone marrow transplantation

Oct 13, 2010

(PhysOrg.com) -- University of Michigan researchers have discovered a new method to prevent the immune-system attacks that often occur following bone marrow transplants.

Bone marrow transplantation can cure patients with leukemia and other cancers even when the disease is resistant to other treatments. The success of this procedure relies on killing cancer cells by using from a bone marrow donor while avoiding an against the patient's organs, which causes a dangerous complication called graft-versus-host disease.

Dr. Ivan Maillard, a U-M Life Sciences Institute professor and an assistant professor of internal medicine at the Medical School, and his lab discovered the new method and say they're encouraged by preliminary results in mouse models. The work, done in collaboration with a team at the U-M Comprehensive Cancer Center, was recently reported in the journal Blood.

The new method works by inhibiting the Notch signaling pathway in immune cells called donor . "Notch is an important pathway that researchers have started to identify multiple functions for in normal tissues and in cancer," said Maillard.

The research team found that Notch-deficient T cells had a markedly reduced ability to produce inflammatory mediators and to damage the normal organs of the recipient mice.

However, unlike previous interventions, Notch inhibition had selective effects and did not cause global immunosuppression. In particular, the Notch-deficient T cells remained able to efficiently kill . This resulted in the elimination of the tumor cells without causing life-threatening graft-versus-host disease.

The LSI team is excited by the future prospects brought by this discovery. In particular, an expanding set of reagents is being developed to target components of Notch signaling that can someday be developed into effective new therapies for patients.

This work was supported by an Innovation Award from the Damon Runyon Cancer Research Foundation, the American Society of Hematology, and the University of Michigan Comprehensive Cancer Center.

Explore further: Researchers find that coronary arteries hold heart-regenerating cells

More information: bloodjournal.hematologylibrary.org/papbyrecent.dtl

Related Stories

Cancer drug shows promise against graft vs. host disease

Jul 10, 2008

A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication ...

Recommended for you

Student seeks to improve pneumonia vaccines

3 hours ago

Almost a million Americans fall ill with pneumonia each year. Nearly half of these cases require hospitalization, and 5-7 percent are fatal. Current vaccines provide protection against some strains of the ...

Seabed solution for cold sores

5 hours ago

The blue blood of abalone, a seabed delicacy could be used to combat common cold sores and related herpes virus following breakthrough research at the University of Sydney.

Better living through mitochondrial derived vesicles

Aug 19, 2014

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

Aug 19, 2014

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

Engineering new bone growth

Aug 19, 2014

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold ...

User comments : 0